RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Chronic kidney disease (CKD) is a major public health problem. It is estimated that 400-600 million adults worldwide have CKD. Furthermore, more than 5% of the adult population has some form of kidney damage. CKD is not an isolated disease, but is strongly linked to other health problems, such as diabetes and cardiovascular diseases (CVD), with high blood pressure as the main indicating risk factor. For example, every year millions die prematurely of CKD-linked CVD alone. However, adverse outcomes of CKD can be prevented through early detection and treatment. Earlier stages of the disease can be detected through routine laboratory measurements. Therefore, a clinical action plan should be developed for each patient, based on the stage of disease. The basic principle of treatment for CKD is to prevent the further deterioration of renal function and to minimize complications, including cardiovascular events. For this purpose, treatment should include specific therapy based on the underlying disease; an evaluation of comorbid conditions; a method of slowing the loss of renal function; the prevention and treatment of CVD as well as complications associated with decreased renal function; and replacement treatment for renal function, using dialysis and transplantation, if signs and symptoms of uremia are present. (Korean J Med 76:521-527, 2009)

번역하기

참고문헌 (Reference)

1 Cannella G, "Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both?" 19 : 399-402, 2006

2 Kwen JH, "The study of anemia in stable chronic kidney disease patients not receiving dialysis treatment" 22 : 63-72, 2003

3 Sica DA, "The risks and benefits of therapy with aldosterone receptor antagonist therapy" 2 : 71-77, 2007

4 김성권, "The Prevalence of Chronic Kidney Disease (CKD) and the Associated Factors to CKD in Urban Korea: A Population-based Cross-sectional Epidemiologic Study" 대한의학회 24 : 11-21, 2009

5 Baigent C, "Study of Heart and Renal Protection (SHARP)" S207-S210, 2003

6 Mann JF, "Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial" 372 : 547-553, 2008

7 Colhoun HM, "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial" 364 : 685-696, 2004

8 National Kidney Foundation, "K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification" 39 (39): S1-S266, 2002

9 National Kidney Foundation, "K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease" 42 (42): S1-S201, 2003

10 National Kidney Foundation, "K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target"